StocktoriaSilexion Therapeutics Corp SLXN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Operating income | -$11.6M | -$12.6M | -$4.7M |
| Net income | -$11.9M | -$16.5M | -$5.1M |
| Operating cash flow | -$10.8M | -$8.4M | -$4.5M |
| Free cash flow | -$10.8M | -$8.4M | -$4.5M |
| Total assets | $7.2M | $2.9M | $5.3M |
| Total liabilities | $4.6M | $6.9M | $2.3M |
| Shareholders' equity | $2.6M | -$4.0M | $3.0M |
| Ratios | |||
| Return on assets | -165.1% | -577.0% | -97.2% |
| Return on equity | -457.6% | 414.1% | -170.2% |
| Current ratio | 2.41 | 0.64 | 2.27 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0002022416 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.